1-3 of 3
Karl-Johan Myrén
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj
Journal: Blood
Blood (2023) 142 (Supplement 1): 1346.
https://doi.org/10.1182/blood-2023-190015
Published: 2023
Journal Articles

Patient Characteristics and Diagnostic Journey of Thrombotic Microangiopathy Associated with a Trigger: A Real-World, Retrospective, Multi-National Study

Yan Wang, Francesca Gatta, Joseph Conyers, Gregor Gibson, Kieran Wynne-Cattanach, Karl-Johan Myrén, Moh-Lim Ong
Journal: Blood
Blood (2023) 142 (Supplement 1): 5526.
https://doi.org/10.1182/blood-2023-179231
Published: 2023
Journal Articles

Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States

Adrian R Levy, Laura Dysart, Yogesh Patel, Andrew Briggs, DPhil, John Schneider, Karl-Johan Myren, MSc, Ioannis Tomazos, PhD MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 4803.
https://doi.org/10.1182/blood-2019-127443
Published: 2019